Center for Molecular Prediction of Inflammatory Bowel Disease

Medicine and Dentistry

1. Adult 16%
2. Age 12%
3. Allergic Rhinitis 6%
4. Anal Fistula 6%
5. Analysis 10%
6. Antibiotics 7%
7. Association 10%
8. Attention Deficit Disorder 6%
9. Autoimmune Pancreatitis 6%
10. Biodiversity 5%
11. Biological Product 14%
12. Birth Outcomes 6%
13. Bowel Resection 6%
14. Cancer Risk 6%
15. Cancer Staging 6%
16. Cervical Cancer 6%
17. Child 8%
18. Childbirth 5%
19. Cohort Analysis 100%
20. Cohort Effect 8%
21. Colectomy 11%
22. Colitis 7%
23. Colonoscopy 5%
24. Colorectal Cancer 14%
25. Consensus 12%
26. Crohn's Disease 52%
27. Cyclosporine 6%
28. Death 5%
29. Desensitization 6%
30. Development 9%
31. Diagnosis 47%
32. Disease Activity 6%
33. Disease Course 18%
34. Diseases 23%
35. Drug 6%
36. Drug Repositioning 6%
37. Drug Therapy 8%
38. Dysplasia 7%
39. Endocrine Disease 6%
40. Eosinophilic Esophagitis 6%
41. Experience 5%
42. Family 6%
43. Family History 6%
44. Fistula 5%
45. Follow up 7%
46. Gastroenterology 6%
47. Genital Wart 6%
48. Glucagon Like Peptide 1 6%
49. Glucocorticoid 5%
50. Glycon 6%
51. Hazard Ratio 37%
52. Hospital 17%
53. Immunosuppressive Drug 7%
54. Incidence 9%
55. Infant 6%
56. Infection 15%
57. Inflammatory Disorder 8%
58. Infliximab 6%
59. Inpatient 65%
60. Lactation 6%
61. Lesion 5%
62. Life 11%
63. Lifestyle 6%
64. Malignant Neoplasm 21%
65. Maturity Onset Diabetes of the Young 7%
66. Meta-Analysis 20%
67. Microbiome 7%
68. Microscopic Colitis 6%
69. Obstructive Lung Disease 6%
70. Odds Ratio 18%
71. Older Adult 12%
72. Patient 81%
73. Patient Registry 6%
74. Patient with Crohn's Disease 18%
75. Patient with Inflammatory Bowel Disease 56%
76. Patient with Ulcerative Colitis 7%
77. Pediatrics 12%
78. Pediatrics Patient 6%
79. Person 10%
80. Personalized Medicine 12%
81. Postpartum Depression 6%
82. Pouchitis 12%
83. Prognosis 7%
84. Prognostication 7%
85. Proportional Hazards Model 7%
86. Rectum Cancer 6%
87. Severe Acute Respiratory Syndrome Coronavirus 2 6%
88. Systematic Review 7%
89. Therapeutic Procedure 44%
90. Tuberculosis 6%
91. Tumor Necrosis Factor 24%
92. Ulcerative Colitis 39%
93. Vedolizumab 13%
94. Vermiform Appendix 6%
95. Woman 20%